Collects data to build predictive models for liver transplant waitlist patients
Collects health data from adults on the liver transplant waitlist to predict dropout risk.
Plain-language title generated from the registry record
Registry title: LEOPARD Training and Validation Data Collection Study
Key facts
- Where
- Aachen, Berlin, Hanover, Jena, Kiel, Leipzig, Münster, Tübingen, and Würzburg, GermanySee the 9 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 70 who are on the waiting list for a liver transplant because of decompensated cirrhosis, another end-stage chronic liver disease, or liver cancer (HCC).
- Age
- 18 to 70 years
- Sex
- All sexes
- Disease stage
- Listed for a liver transplant for decompensated cirrhosis, for another chronic end-stage liver disease such as primary biliary cholangitis or primary sclerosing cholangitis, or for HCC (diagnosed by Barcelona/EASL criteria or by tissue test).
Main reasons for not taking part
- Tumor growing into the portal or hepatic veins on imaging, including portal vein thrombosis stage 1
- HCC that has spread outside the liver
- Under legal protection (justice, tutorship or curatorship)
- On AME (state medical aid)
- Taking part in the LEOPARD PVC 1 study of WP2
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT06675604, who can take part
Where in Germany
- Department for General, Visceral, Pediatric and Transplant Surgery, Universitätsklinikum AachenAachen, GermanyContact: Thomas Vogel, MD-PHDTaking people
- Charité Universitätsmedizin BerlinBerlin, GermanyContact: Nathanael Raschzok, MD-PHDTaking people
- Gastroenterology, Hepatology, Infectious Diseases and Endocrinology (GHIE) Medizinische Hochschule HannoverHanover, GermanyContact: Richard Taubert, MD-PHDTaking people
- Universitätsklinikum JenaJena, GermanyContact: Falk Rauchfuss, MD-PHDTaking people
- Universitätsklinikum Schleswig - Holstein | UKSH · Transplantation MedicineKiel, GermanyContact: Felix Braun, MD-PHDTaking people
- Universität LeipzigLeipzig, GermanyContact: Thomas Berg, MD-PHDTaking people
- Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Universitätsklinikum MünsterMünster, GermanyContact: Andreas Pascher, MD-PHDTaking people
- Klinik für Allgemeine, Viszeral- und Transplantationschirurgie, Universitätsklinikum TübingenTübingen, GermanyContact: Silvio Nadalin, MD-PHDTaking people
- Universitätsklinikum WürzburgWürzburg, GermanyContact: Johan Lock, MD-PHDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Trial code
- NCT06675604
- Record updated
- 29 July 2026
- Original description
Intro:Read full original descriptionShow less
Data Collection to Design and Validate LEOPARD Predictive Models of Delisting in Liver Transplant Candidates
Intro:
The present clinical research protocol is part of the LEOPARD European project (Grant n° 101080964 Horizon Europe) which aims to design and validate new predictive models of mortality among liver transplantation (LT) candidates. MELD based-liver graft allocation systems have become increasingly inaccurate over the last decade to predict mortality/dropout of liver transplantation (LT) candidates on the waitlist (WL). Wide disparities in mortality/dropout on the WL also exist across European countries, ranging from 5 to 30% according to transplantation indications and countries. In this setting, the European Commission- Horizon Europe funded-LEOPARD project intends to design new, 2nd generation, AI-machine learning-based predictive models of delisting in LT candidates, to better serve on time patients with the highest risk of dropout on the WL and to improve equity of access to LT across Europe.
Hypothesis/Objective:
The scientific justification of the LEOPARD TVDCS is therefore to collect a large set of data in liver transplantation candidates listed in Europe a) to design and b) to validate LEOPARD 2nd generation AI-based predictive models of mortality/dropout The primary objective is to develop new predictive models of mortality/drop out on the waitlist in patients with decompensated cirrhosis, or other end-stage chronic liver diseases, and in patients listed for Hepato-cellular carcinoma (HCC).
Method:
Longitudinal multicenter prospective health care data collection cohort study in 2 sets : Training/development set : Prospective health care data collection in 3,000 patients listed in 50 centres across 7 countries and Validation set: Prospective health care data collection in 1,500 subsequent patients listed in the same 50 centres.
Inclusion: Adult [age 18;70] patients listed for:; decompensated cirrhosis as primary diagnosis, irrespective of liver disease etiology (subset 1) OR; other chronic end-stage liver diseases requiring LT, to be listed under a MELD-based allocation system (examples: primary biliary cholangitis, primary sclerosing cholangitis etc…) (subset 2) OR; HCC* as primary diagnosis, whatever the etiology of the underlying liver disease with or without underlying cirrhosis (subset 3). (HCC diagnosed on Barcelona/EASL criteria or histologically proven. HCC meeting or not Milan criteria, as per center practice.); Patients registered on national waiting lists under the MELD offering schemes, regardless of extra MELD points and MELD exceptions are affected or not; Patient (or trusted person, family member or close relation, if the patient is unable to be informed) who has been informed and did not express opposition to data collection; (*Of note, enrolment of patients with T1 tumors (1 single tumor < 2 cm diameter) not amenable to loco-regional therapies because of decompensation, and prioritized under the MELD system, will be allowed in Subset 1.).
Exclusion: Tumor vascular invasion (portal or hepatic veins) evidenced by imaging at pre transplantation work-up, including portal vein thrombosis stage 1; Extra-hepatic metastasis of HCC, as assessed by sectional imaging, functional imaging (18 FDG PET CT/MRI) or histologically proven; Patients who are under safeguard of justice or tutorship or curatorship; Patient on AME (state medical aid); Participation to LEOPARD PVC 1 study of WP2.